收费全文 | 25201篇 |
免费 | 1804篇 |
国内免费 | 732篇 |
耳鼻咽喉 | 96篇 |
儿科学 | 357篇 |
妇产科学 | 272篇 |
基础医学 | 1862篇 |
口腔科学 | 276篇 |
临床医学 | 2361篇 |
内科学 | 5655篇 |
皮肤病学 | 364篇 |
神经病学 | 1789篇 |
特种医学 | 234篇 |
外国民族医学 | 1篇 |
外科学 | 2003篇 |
综合类 | 2392篇 |
现状与发展 | 2篇 |
预防医学 | 672篇 |
眼科学 | 262篇 |
药学 | 6036篇 |
8篇 | |
中国医学 | 587篇 |
肿瘤学 | 2508篇 |
2023年 | 482篇 |
2022年 | 592篇 |
2021年 | 994篇 |
2020年 | 966篇 |
2019年 | 1003篇 |
2018年 | 900篇 |
2017年 | 1007篇 |
2016年 | 934篇 |
2015年 | 972篇 |
2014年 | 1266篇 |
2013年 | 2594篇 |
2012年 | 1139篇 |
2011年 | 1359篇 |
2010年 | 1015篇 |
2009年 | 1104篇 |
2008年 | 1132篇 |
2007年 | 1065篇 |
2006年 | 956篇 |
2005年 | 822篇 |
2004年 | 725篇 |
2003年 | 641篇 |
2002年 | 583篇 |
2001年 | 487篇 |
2000年 | 424篇 |
1999年 | 367篇 |
1998年 | 348篇 |
1997年 | 319篇 |
1996年 | 271篇 |
1995年 | 286篇 |
1994年 | 260篇 |
1993年 | 215篇 |
1992年 | 203篇 |
1991年 | 203篇 |
1990年 | 178篇 |
1989年 | 172篇 |
1988年 | 143篇 |
1987年 | 146篇 |
1986年 | 110篇 |
1985年 | 236篇 |
1984年 | 223篇 |
1983年 | 141篇 |
1982年 | 183篇 |
1981年 | 151篇 |
1980年 | 108篇 |
1979年 | 84篇 |
1978年 | 63篇 |
1977年 | 57篇 |
1976年 | 39篇 |
1975年 | 15篇 |
1973年 | 14篇 |
Areas covered: We summarize the recent clinical successes of CTLA-4 inhibitors and place a strong emphasis on those in early phase clinical trials, often in combination with other immune check-point inhibitors, i.e., programmed cell death protein 1 (PD-1) and BRAF/mitogen-activated protein kinase inhibitors.
Expert opinion: Recent phase I and phase II clinical trials confirm the efficacy of anti-CTLA-4 therapy for treatment of cancers such as renal cell carcinoma. These studies also indicated increased efficacy with combined immune checkpoint blockade with PD-1 or Ras/Raf/mitogen-activated protein kinase/ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) inhibitors. Researchers must search for new immune targets that may enable more effective and safe immune checkpoint blockade and cancer therapy. This goal may be achieved by next-generation combination therapies to overcome immune checkpoint therapy resistance. 相似文献
Areas covered: This review comprises a summary of patent applications (2013–2018) of SGLT2 inhibitors with focus on chemical structural advancement and therapeutic potentials in the management of diabetes and related disorders.
Expert opinion: SGLT2 inhibitors exert multiple metabolic benefits, including reduced glycated hemoglobin (HbA1c), improved glycemic control (fasting and postprandial), reduced body weight, reduced systolic and diastolic blood pressure and improved HDL cholesterol. Due to the virtue of no interference with insulin action and secretion, their efficacy remains the same even in presence of progressive β cell failure in type 2 diabetes. Additionally, few members of this class have been reported to exhibit cardioprotective, renoprotective, and anticancer activity. However, more study on the long-term outcomes in patients taking SGLT2 inhibitors is warranted. 相似文献
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献